ICT - MILSTEIN   05483
INSTITUTO DE CIENCIA Y TECNOLOGIA "DR. CESAR MILSTEIN"
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Monophosphoryl lipid A as adjuvant for recombinant influenza nucleoprotein vaccine in mice.
Autor/es:
CARGNELUTTI DIEGO ESTEBAN; SÁNCHEZ MARÍA VICTORIA; BOADO LORENA; ALVAREZ PAULA; MATTION NORA; SCODELLER EDUARDO ALBERTO
Lugar:
Buenos Aires
Reunión:
Congreso; First French-Argentine Immunology Congress.; 2010
Resumen:
Influenza is one of the most important respiratory pathogens
worldwide. Vaccination is the best way to control influenza.
Lipopolysaccharides (LPS) trigger innate immune response
through activation of Toll-like receptor 4 (TLR4). Such responses
may be exploited for the development of adjuvants and in
particular monophosphoryl lipid A (MPLA) obtained by controlled
hydrolysis of LPS of Salmonella minnesota. The use of
influenza A virus recombinant nucleoprotein (rNP) as a vaccine
antigen, stems from the fact that NP show less antigenic variation
than the influenza virus surface glycoproteins, haemagglutinin
and neuraminidase. The object of this work is to describe
the production and immunogenicity of rNP from influenza A
virus formulated with MPLA as a vaccine. Method: Homologous
prime and boost subcutaneous vaccination of BALB/c mice with
10ug of the rNP (control group) and 10ug of rNP formulated
with 25ug of MPLA (experimental group) were administered 3
weeks apart. On day 60 post prime, serum samples were collected
to evaluate the specific titre of total IgG, IgG1 and IgG2a
isotypes. At the same time, culture supernatants of spleen cells
were collected, after antigen stimulation to test the presence of
IFNg by ELISA. Result: Subcutaneous injection of rNP with MPLA
into BALB/c mice elicited both humoral and cellular immune
responses. Animals injected with rNP/MPLA developed NPspecific
antibodies, with total IgG titers of 11,200 and increase
the ratio IgG2a/IgG1 from 0.045 to 0.96. In addition, the rNP/
MPLA vaccine induced a significant different on the production
of IFNg, within control group and experimental group. Conclusion:
This study demonstrates that the formulation of rNPr with
MPLA induces a strong specific Th1 type immune response,
humoral as well as cellular. This is a first step to demonstrate
that MPLA can be use as an adjuvant in the formulation of a
recombinant NP influenza vaccine.